cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.21618672
title: Band-Limited Maximizers for a Fourier Extension Inequality on the Circle, II

description: Among the class of functions on the circle with Fourier modes up to degree 120, constant functions are the unique real-valued maximizers for the endpoint Tomas-Stein inequality.
DOI: 10.6084/m9.figshare.21618672.v1
title: Band-Limited Maximizers for a Fourier Extension Inequality on the Circle, II

description: Among the class of functions on the circle with Fourier modes up to degree 120, constant functions are the unique real-valued maximizers for the endpoint Tomas-Stein inequality.
DOI: 10.3886/p54p-g882
title: Indonesia Compact - Green Prosperity: Participatory Land Use Planning: Design Report (Original)
DOI: 10.34740/kaggle/dsv/5766690
title: Deep Shape From Template Dataset(DSfTD)
DOI: 10.21430/m3fl8hief7
title: T and B Cell Responses across Autoimmune Diseases

description: The study aims to establish whether defects in immune cell function are shared across multiple autoimmune diseases and whether those problems match to similar genes in the cells.
DOI: 10.21430/m35so7682u
title: Romiplostim (Nplate) Efficacy Study with or without Pegfilgrastim (Neulasta) in a Rhesus Macaque H-ARS Model

description: Nplate, with and without Neulasta, was given to irradiated rhesus macaques to determine whether Nplate administration improved survival, and whether co-administration of Nplate improved survival.
DOI: 10.21430/m3tp2s2dbr
title: Genomics of Kidney Transplantation (GEN-03)

description: The major aim of this research study is to investigate the relationship between genetic variation in DNA (inherited code material in the cells of the body) and factors affecting transplant outcomes, like the drugs people receive or the way their immune systems work, for example. To do this, investigators will collect blood samples from participants. Genetic material will be separated from each blood sample and analyzed, looking for genetic variation.
DOI: 10.21430/m3bjt9805b
title: Tocilizumab (TCZ) in New-onset Type 1 Diabetes (ITN058AI)

description: Type 1 diabetes mellitus (T1DM) is an autoimmune disease. Based on previous research, study doctors think that giving medicines to affect the immune system soon after diabetes is diagnosed may stop, delay or decrease the destruction of beta cells, resulting in better glucose control. Researchers believe that tocilizumab could have some effect on the cells in the immune system that are thought to be involved in the development of type 1 diabetes. This study will test whether tocilizumab can help preserve or delay destruction of remaining beta cells in people recently diagnosed type 1 diabetes.
DOI: 10.21430/m3vxkexmq9
title: Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Kidney Cancer Undergoing Surgery

description: This pilot clinical trial studies stereotactic body radiation therapy in treating patients with metastatic kidney cancer undergoing surgery. Stereotactic radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue.
DOI: 10.21430/m3cppwclw4
title: Immune memory to COVID-19 vaccines

description: In this study, SARS-CoV-2-spike-specific immune responses to Moderna mRNA-1273, Pfizer/BioNTech BNT162b2, Janssen Ad26.COV2.S, and Novavax NVX-CoV2373 COVID-19 vaccines were examined longitudinally for 6 months.
DOI: 10.21430/m33regwy6x
title: Sex and Dose Rate Effects in High Throughput Cytogenetics

description: To study Age, Sex and Dose rate as confounders for high throughput cytogenetic assays (CBMN and DCA)
DOI: 10.21430/m3c5m9styc
title: Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE) (ALE06)

description: This trial seeks to describe the effect of withdrawal from mycophenolate mofetil (MMF) on risk of clinically significant disease reactivation in quiescent SLE patients who have been on long-term MMF therapy.
DOI: 10.21430/m3i68fwbgk
title: Cytotoxic T cells targeting spike glycoprotein are associated with hybrid immunity to SARS-CoV-2

description: FCS and workspace files from ICS experiments
DOI: 10.21430/m3lnhd4pzm
title: Secretory activity of human bone marrow mesenchymal stem cells

description: Our research studied the effect of topographical cues of the culture substrate on the secretome of bone marrow-derived mesenchymal stem cells. Conditioned media and lysate samples of human bone marrow-derived mesenchynal stem cells cultured on the topographical substrates were sent to Raybiotech Inc. Services for protein detection. They performed a Quantibody® Multiplex ELISA of 200 human proteins. These results were used to further perform a differential statistical analysis on the expression of the quantified proteins using R statistical software. Differential protein expression and gene ontology analyses identified bio processes associated with immune regulation.
DOI: 10.21430/m3m8ax1ti9
title: Drivers of Heterogeneity in Synovial Fibroblasts in Rheumatoid Arthritis.

description: Inflammation of non-barrier immunologically quiescent tissues is associated with a massive influx of blood-borne innate and adaptive immune cells. Cues from the latter are likely to alter and expand activated states of the resident cells. However, local communications between immigrant and resident cell types in human inflammatory disease remain poorly understood. Here, we explored drivers of fibroblasts-like synoviocytes (FLS) heterogeneity in inflamed joints of rheumatoid arthritis (RA) patients using paired single cell RNA and ATAC sequencing (scRNA/ATAC-seq), multiplexed imaging, and spatial transcriptomics along with in vitro modeling of cell extrinsic factor signaling. These analyses suggest that local exposures to myeloid and T cell derived cytokines, TNF, IFN, IL-1, or lack thereof, drive four distinct FLS states some of which closely resemble fibroblast states in other disease-affected tissues including skin and colon. Our results highlight a role for concurrent, spatially distributed cytokine signaling within the inflamed synovium.
DOI: 10.21430/m365o4lm7j
title: Waning and boosting of antibody Fc-effector functions upon SARS-CoV-2 vaccination

description: Here we deeply profiled the functional humoral immune response induced by CoronaVac and Pfizer/BNT162b2 vaccines. Particularly we analyzed how the vaccine-induced functional responses waned with time and characterized the boosting capacity of the BNT162b2 vaccine, which enhanced the overall humoral responses of CoronaVac primed vaccinees to levels that were higher than the peak responses seen in the recipients vaccinated with two doses of the CoronaVac or BNT162b2 vaccines. We identified that Fc-receptor binding antibodies waned much faster than binding IgG1. Moreover, while antibody functions were induced against Omicron following BNT162b2 vaccination, these responses waned rapidly over time and were not observed in the setting of CoronaVac vaccination. Importantly, mRNA boosting of the CoronaVac response yielded a striking enhancement of functional humoral immunity across VOCs, including Omicron. These data collectively point to marked vaccine platform-based differences in peak functional humoral protection, as well as their distinct waning profiles. This phenotype can be enhanced and, in several cases, functionally expanded by heterologous boosting.
DOI: 10.21430/m3acsp6bvr
title: A serological assay for seroconversion detection

description: A serological enzyme-linked immunosorbent assay to detect SARS-CoV-2 seroconversion in humans
DOI: 10.21430/m3n3q6qzuy
title: Respiratory mucosal immunity against SARS-CoV-2 following mRNA vaccination

description: To compare traditional humoral and cellular immune response with mucosal immune response to vaccination or infection (convalescent) and to test intranasal vaccination in a mouse model.
DOI: 10.21430/m3xhdqgswq
title: Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants

description: To study the durability of booster mRNA Vaccine against SARS-CoV-2 Subvariants BA.2.12.1, BA.4, and BA.5
DOI: 10.21430/m30muqm1bq
title: Retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants

description: Post-vaccine sera were collected from participants in the PARIS study to determine neutralizing activity against 7 emerging variants
DOI: 10.21430/m3x4d5l0ft
title: Neutralization of SARS-CoV-2 Variants of Concern Harboring Q677H

description: To investigate the neutralization sensitivity of variants containing the non-RBD mutation Q677H, including B.1.525 (Nigerian isolate) and Bluebird (U.S. isolate) variants
DOI: 10.21430/m3xuz51af8
title: The COVID-19 vaccine concerns scale: Development and validation of a new measure

description: To develop and validate a scale for self-reported COVID-19 vaccine concerns among U.S. emergency medical services (EMS) and healthcare professionals.
DOI: 10.21430/m397iy0tsf
title: COVID-19 Vaccinations in EMS Professionals: Prevalence and Predictors

description: To better understand EMS professionals decisions to receive or decline a COVID-19 vaccine
DOI: 10.21430/m3154e9f43
title: An Opportunity to Understand Concerns about COVID-19 Vaccination: Perspectives from EMS Professionals

description: To understand EMS professionals’ perspectives regarding COVID-19 vaccination
DOI: 10.21430/m3agu15equ
title: Closing the Gap on COVID-19 Vaccinations in First Responders and Beyond: Increasing Trust

description: To investigate the extent to which first responders in the U.S. trusted various information sources to provide reliable information about COVID-19 vaccines
DOI: 10.21430/m3a8f4a3nu
title: Symptomology following mRNA vaccination against SARS-CoV-2.

description: To address existing information gaps regarding local and systemic symptoms in health care workers following mRNA vaccination against SARS-CoV-2.
DOI: 10.21430/m3k6396yai
title: Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2.

description: To evaluate SARS-CoV-2-specific antibody responses after the first and second doses of the BNT162b2 (Pfizer–BioNTech) mRNA vaccine in a large and diverse cohort of healthcare workers.
DOI: 10.21430/m3c2q25enq
title: Practice Patterns and Patient Outcomes After Widespread Adoption of Remote Heart Failure Care

description: To evaluate whether remote visits (video or telephone) were associated with different patient usage, clinician practice patterns, and outcomes.
DOI: 10.21430/m3o5e1q8jy
title: Optimizing prevalence estimates for a novel pathogen by reducing uncertainty in test characteristics

description: To estimate the diagnostic test sensitivity and specificity through jointly modeling field data and validation data using standard Bayesian techniques.
DOI: 10.21430/m38m5au5pj
title: SARS-CoV-2 Serosurveys: How antigen, isotype and threshold choices affect the outcome

description: To reveal the importance of evaluating serosurvey tools for antigen, isotype, and threshold-specific sensitivity and specificity, in order to interpret qualitative serosurvey outcomes reliably and consistently across study populations.
DOI: 10.21430/m32ksb7vcx
title: D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization

description: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein acquired a D614G mutation early in the pandemic that confers greater infectivity and is now the globally dominant form. To determine whether D614G might also mediate neutralization escape that could compromise vaccine efficacy, sera from spike-immunized mice, nonhuman primates, and humans were evaluated for neutralization of pseudoviruses bearing either D614 or G614 spike. In all cases, the G614 pseudovirus was moderately more susceptible to neutralization. The G614 pseudovirus also was more susceptible to neutralization by receptor-binding domain (RBD) monoclonal antibodies and convalescent sera from people infected with either form of the virus. Negative stain electron microscopy revealed a higher percentage of the 1-RBD up conformation in the G614 spike, suggesting increased epitope exposure as a mechanism of enhanced vulnerability to neutralization. Based on these findings, the D614G mutation is not expected to be an obstacle for current vaccine development.
DOI: 10.21430/m3q3c0udd8
title: SARS-CoV-2 -specific immune responses in boosted vaccine recipients with breakthrough infections during the Omicron variant surge

description: To analyze SARS-CoV-2–specific antibody and cellular responses in healthy vaccine recipients who experienced breakthrough infections during the Omicron surge.
DOI: 10.21430/m32ekwillc
title: Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2

description: Examine the sensitivity of Omicron sub-lineages to neutralizing antibodies from mRNA-vaccinated, boosted and recovered COVID-19 patients.
DOI: 10.6084/m9.figshare.23099894
title: SourceData_MainFigure5_EDFigure5_EDFigure6

description: Source data for Figure 5, Extended Data Figure 5, Extended Data Figure 6
DOI: 10.6084/m9.figshare.23099894.v1
title: SourceData_MainFigure5_EDFigure5_EDFigure6

description: Source data for Figure 5, Extended Data Figure 5, Extended Data Figure 6
DOI: 10.21430/m3wd13ivpv
title: Neutralization of the SARS-CoV-2 Deltacron and BA.3 Variants

description: To examine the ability of deltacron variants to evade immunity induced by either vaccination or previous infection
DOI: 10.21430/m3743kkghe
title: Perspectives of Volunteer Firefighters during the COVID-19 Pandemic: Stumbling Blocks and Silver Linings

description: To improve our understanding of the impacts of this pandemic on volunteer firefighters in relation to both their volunteer service roles and as members of their local communities
DOI: 10.21430/m3vwj6w5m3
title: Ultrasensitive detection of salivary SARS-CoV-2 IgG antibodies in individuals with natural and COVID-19 vaccine-induced immunity

description: To assess the feasibility of a highly sensitive immunoassay method to detect IgG and IgA antibodies against SARS-CoV-2 spike protein receptor binding domain (RBD) in saliva from individuals with natural or vaccine-induced COVID-19 immunity.
DOI: 10.21430/m37s4576zh
title: Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study

description: To evaluate the effectiveness and safety of nAb titer-defined COVID-19 convalescent plasma (CCP) in adults admitted to an academic referral hospital.
DOI: 10.21430/m3nc2l1uyi
title: Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate

description: Assessing and studying the potential neutralizing capacity of NDV vector vaccines expressing the spike protein of SARS-CoV-2
DOI: 10.21430/m3d2vnzc41
title: Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization

description: The newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) highlights the urgent need for assays that detect protective levels of neutralizing antibodies. We studied the relationship among anti-spike ectodomain (anti-ECD), anti-receptor-binding domain (anti-RBD) IgG titers, and SARS-CoV-2 virus neutralization (VN) titers generated by 2 in vitro assays using convalescent plasma samples from 68 patients with COVID-19. We report a strong positive correlation between both plasma anti-RBD and anti-ECD IgG titers and in vitro VN titers. The probability of a VN titer of greater than or equal to 160, the FDA-recommended level for convalescent plasma used for COVID-19 treatment, was greater than or equal to 80 percent when anti-RBD or anti-ECD titers were greater than or equal to 1:1350. Of all donors, 37 percent lacked VN titers of greater than or equal to 160. Dyspnea, hospitalization, and disease severity were significantly associated with higher VN titer. Frequent donation of convalescent plasma did not significantly decrease VN or IgG titers. Analysis of 2814 asymptomatic adults found 73 individuals with anti-ECD IgG titers of greater than or equal to 1:50 and strong positive correlation with anti-RBD and VN titers. Fourteen of these individuals had VN titers of greater than or equal to 1:160, and all of them had anti-RBD titers of greater than or equal to 1:1350. We conclude that anti-RBD or anti-ECD IgG titers can serve as a surrogate for VN titers to identify suitable plasma donors. Plasma anti-RBD or anti-ECD titers of greater than or equal to 1:1350 may provide critical information about protection against COVID-19 disease.
DOI: 10.21430/m3sqteah4v
title: Preserved recognition of Omicron spike following COVID-19 messenger RNA vaccination in pregnancy

description: This study aims to test whether vaccine-induced antibodies raised during pregnancy continue to bind to and leverage Fc receptors to protect against variants of concern including the Omicron variant.
DOI: 10.21430/m3dbdojhgh
title: Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

description: To investigate vaccine-induced antibody responses in patients with NHL/CLL against SARS-CoV-2 strains
DOI: 10.21430/m3fobftupv
title: Functional Effects of Cardiomyocyte Injury in COVID-19

description: To use machine learning and in vitro models to identify plausible mechanisms of cardiac disease in COVID-19 patients.
DOI: 10.21430/m3syjz2g47
title: Cas13d knockdown of lung protease Ctsl prevents and treats SARS-CoV-2 infection

description: To study whether targeting lung protease mRNA by Cas13d nanosystem represents a unique strategy for controlling SARS-CoV-2 infection and to investigate if CRISPR can be used as a potential treatment for SARS-CoV-2 infection.
DOI: 10.21430/m3gal2kqys
title: Immunogenicity of NDV-HRP-S in Sprague Dawley Rats

description: Assessing the immunogenicity of live Newcastle disease virus vector expressing a pre-fusion stabilized version of the spike protein, NDV-HRP-S, in Sprague Dawley Rats administered intranasally (IN), intramuscularly (IM), or IN followed by IM.
DOI: 10.21430/m3m5btsaj7
title: Reduced pathogenicity of the SARS-CoV-2 omicron variant in hamsters

description: To study if the pathogenicity of SARS-CoV-2 Omicron is less than that of prior SARS-CoV-2 variants in Syrian golden hamsters
DOI: 10.21430/m3wrg2rj32
title: Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody

description: To evaluate the binding activity and potency of ADG-2 against a large panel of sarbecoviruses
DOI: 10.21430/m3fvtbwjg1
title: Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions

description: To identify a panel of cross-reactive antibodies that recognize the S antigen from multiple coronaviruses
DOI: 10.21430/m3xfkmumiv
title: Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses

description: To evaluate the protective immunity of RBD-scNP adjuvanted with TLR7 and TLR8 agonist 3M-052 vaccines against SARS-CoV-2 and beta coronaviruses that circulate in macaques.
DOI: 10.21430/m30rr7bfu2
title: SARS-CoV-2 vaccines elicit durable immune responses in infant rhesus macaques

description: To assess the safety and immunogenicity of two SARS-CoV-2 vaccines (mRNA-LNP and Protein+3M052-SE) in infant rhesus macaques
DOI: 10.21430/m3qm7oztac
title: COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge

description: To evaluate the immune response and potential for immunopathology in mice vaccinated with research-grade mRNA-1273
DOI: 10.21430/m3ruavh163
title: Role of miR-2392 in driving SARS-CoV-2 infection

description: To evaluate the role of a circulating microRNA, miR-2392, as a potential biomarker for COVID-19 and to develop a potential COVID-19 therapeutic and antiviral to inhibit miR2392.
DOI: 10.21430/m306pugy2i
title: Antibody binding and neutralization of live SARS-CoV-2 variants including BA.4/5 following booster vaccination of patients with B-cell malignancies

description: To determine the antibody responses after booster vaccination in patients with B-cell malignancies against SARS-CoV-2 variants including BA.4/5
DOI: 10.21430/m3yqrthk52
title: A bivalent SARS-CoV-2 monoclonal antibody combination does not impact the immunogenicity of a vector-based COVID-19 vaccine in macaques

description: To assess the impact of potent neutralizing SARS-CoV-2 mAbs on the immunogenicity of a genetic-based, prototypic viral vector-based SARS-CoV-2 vaccine when they are co-administered.
DOI: 10.21430/m3kar6h0ro
title: Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2

description: To examine the neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2 against sera from vaccinated healthcare workers, hospitalized BA.1-wave patients, and BA.4/5-wave patients
DOI: 10.21430/m31cxjd6ik
title: Evasion of neutralizing antibody responses by the SARS-CoV-2 BA.2.75 variant

description: To examine the neutralizing antibody escape of BA.2.75 in mRNA-vaccinated and BA.1-infected individuals, as well as the molecular basis underlying the functional changes (including BA.2.75 infectivity, S processing, and fusogenicity)
DOI: 10.21430/m34ktykx2d
title: In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies

description: To determine whether SARS CoV-2 RBD and NTD antibodies mediate enhanced immunopathology in macaque and mice, and if this enhancement will occur in the setting of human infection or vaccination.
DOI: 10.21430/m3nh5eql6v
title: Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals

description: To compare SARS-CoV-2-specific CD4+ and CD8+ T cells against the B.1.1.7, B.1.351, P.1, and CAL.20C lineages in COVID-19 convalescents and in recipients of the Moderna (mRNA-1273) or Pfizer/BioNTech (BNT162b2) COVID-19 vaccines.
DOI: 10.21430/m3geiofi1n
title: Correlates of Neutralization against SARS-CoV-2 Variants of Concern by Early Pandemic Sera

description: To investigate cross-neutralization of the B.1.1.7 and B.1.351 SARS-CoV-2 variants in a well-characterized cohort of early pandemic convalescent subjects
DOI: 10.21430/m3thlz4ope
title: Immune cells in bronchoalveolar lavage fluid of Ugandan adults who resist versus those who develop latent Mycobacterium tuberculosis infection

description: Bronchoscopy was performed on 21 healthy long-term Ugandan RSTR and 25 LTBI participants. Immune cell distributions in BAL and peripheral blood were compared by differential cell counting and flow cytometry.
DOI: 10.21430/m35rxa4o4r
title: Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris (PAUSE)

description: The purpose of this study is to determine if the use of ustekinumab, followed by abatacept, will prevent relapse in people with moderate to severe plaque psoriasis.
DOI: 10.6084/m9.figshare.22954172
title: SourceData_MainFigure4_EDFigure4

description: Source data for Main Figure 4 and Extended Data Figure 4
DOI: 10.6084/m9.figshare.22954172.v1
title: SourceData_MainFigure4_EDFigure4

description: Source data for Main Figure 4 and Extended Data Figure 4
DOI: 10.6084/m9.figshare.22954142
title: SourceData_MainFigure3_EDFigure3

description: Source Data for Main Figure 3 and Extended Data Figure 3
DOI: 10.6084/m9.figshare.22954142.v1
title: SourceData_MainFigure3_EDFigure3

description: Source Data for Main Figure 3 and Extended Data Figure 3
DOI: 10.6084/m9.figshare.22941839
title: SourceData_MainFigure2_EDFigure1c

description: Source Data for Main Figure 2 and Extended Data Figure 1c
DOI: 10.6084/m9.figshare.22941839.v1
title: SourceData_MainFigure2_EDFigure1c

description: Source Data for Main Figure 2 and Extended Data Figure 1c
DOI: 10.6084/m9.figshare.22941740.v1
title: SourceData_MainFigure1_EDFigure1_EDFigure2

description: Source Data for Main Figure 1 and Extended Data Figures 1 and 2